{"transactions":[{"id":779327,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47355,"kind":"person","name":"Schalop Lee Troy","position":1,"cik":"0002072339","reported_name":"Schalop Lee Troy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock purchase warrant (Right to Buy)","published_at":"2026-05-14T20:10:11.000Z","date":"2026-05-12","kind":"purchase","planned":false,"acquired":false,"shares":48544,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were acquired in the issuer's offering of securities that closed on May 14, 2026. The warrants are exercisable commencing on November 14, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities were acquired in the issuer's offering of securities that closed on May 14, 2026. The warrants are exercisable commencing on November 14, 2026."}],"balance_after":48544,"derivative":{"exercise_price":2.27,"expiration_date":"2031-11-13","underlying":"Common Stock","underlying_shares":48544},"source":{"system":"sec-edgar","filing":"0001493152-26-023083","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226023083/ownership.xml","form_type":"4"}},{"id":779326,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47355,"kind":"person","name":"Schalop Lee Troy","position":1,"cik":"0002072339","reported_name":"Schalop Lee Troy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock, $0.001 par value","published_at":"2026-05-14T20:10:11.000Z","date":"2026-05-12","kind":"purchase","planned":false,"acquired":true,"shares":48544,"price":2.06,"value":100000.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were acquired in the issuer's offering of securities that closed on May 14, 2026. The warrants are exercisable commencing on November 14, 2026."}],"balance_after":48544,"source":{"system":"sec-edgar","filing":"0001493152-26-023083","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226023083/ownership.xml","form_type":"4"}},{"id":779325,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock purchase warrant (Right to Buy)","published_at":"2026-05-14T20:10:08.000Z","date":"2026-05-12","kind":"purchase","planned":false,"acquired":false,"shares":48544,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were acquired in the issuer's offering of securities that closed on May 14, 2026. The warrants are exercisable commencing on November 14, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities were acquired in the issuer's offering of securities that closed on May 14, 2026. The warrants are exercisable commencing on November 14, 2026."}],"balance_after":48544,"derivative":{"exercise_price":2.27,"expiration_date":"2031-11-13","underlying":"Common Stock","underlying_shares":48544},"source":{"system":"sec-edgar","filing":"0001493152-26-023082","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226023082/ownership.xml","form_type":"4"}},{"id":779324,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock, $0.001 par value","published_at":"2026-05-14T20:10:08.000Z","date":"2026-05-12","kind":"purchase","planned":false,"acquired":true,"shares":48544,"price":2.06,"value":100000.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were acquired in the issuer's offering of securities that closed on May 14, 2026. The warrants are exercisable commencing on November 14, 2026."}],"balance_after":94303,"source":{"system":"sec-edgar","filing":"0001493152-26-023082","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226023082/ownership.xml","form_type":"4"}},{"id":940100,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T21:05:14.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":28844,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 12-month period commencing February 9, 2026."}],"balance_after":28844,"derivative":{"exercise_price":3.49,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":28844},"source":{"system":"sec-edgar","filing":"0001493152-26-002024","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226002024/ownership.xml","form_type":"4"}},{"id":940099,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T21:05:14.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing February 9, 2026."}],"balance_after":25000,"derivative":{"exercise_price":3.49,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001493152-26-002024","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226002024/ownership.xml","form_type":"4"}},{"id":940098,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":69441,"kind":"person","name":"Maccecchini Maria-Luisa","position":1,"cik":"0001315018","reported_name":"Maccecchini Maria-Luisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T21:05:12.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":21152,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 12-month period commencing February 9, 2026."}],"balance_after":21152,"derivative":{"exercise_price":3.49,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":21152},"source":{"system":"sec-edgar","filing":"0001493152-26-002025","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226002025/ownership.xml","form_type":"4"}},{"id":940097,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":69441,"kind":"person","name":"Maccecchini Maria-Luisa","position":1,"cik":"0001315018","reported_name":"Maccecchini Maria-Luisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T21:05:12.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing February 9, 2026."}],"balance_after":25000,"derivative":{"exercise_price":3.49,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001493152-26-002025","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226002025/ownership.xml","form_type":"4"}},{"id":940096,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47355,"kind":"person","name":"Schalop Lee Troy","position":1,"cik":"0002072339","reported_name":"Schalop Lee Troy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T21:05:09.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":18460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 12-month period commencing February 9, 2026."}],"balance_after":18460,"derivative":{"exercise_price":3.49,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":18460},"source":{"system":"sec-edgar","filing":"0001493152-26-002026","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226002026/ownership.xml","form_type":"4"}},{"id":940095,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47355,"kind":"person","name":"Schalop Lee Troy","position":1,"cik":"0002072339","reported_name":"Schalop Lee Troy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T21:05:09.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing February 9, 2026."}],"balance_after":25000,"derivative":{"exercise_price":3.49,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001493152-26-002026","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226002026/ownership.xml","form_type":"4"}},{"id":940111,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":69443,"kind":"person","name":"Chandru Vijay","position":1,"cik":"0001813367","reported_name":"Chandru Vijay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T16:05:11.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":17307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 12-month period commencing February 9, 2026."}],"balance_after":17307,"derivative":{"exercise_price":3.49,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":17307},"source":{"system":"sec-edgar","filing":"0001493152-26-002023","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813367/000149315226002023/ownership.xml","form_type":"4"}},{"id":940110,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":69443,"kind":"person","name":"Chandru Vijay","position":1,"cik":"0001813367","reported_name":"Chandru Vijay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T16:05:11.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing February 9, 2026."}],"balance_after":25000,"derivative":{"exercise_price":3.49,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001493152-26-002023","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813367/000149315226002023/ownership.xml","form_type":"4"}},{"id":940109,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":69442,"kind":"person","name":"Silberstein David S.","position":1,"cik":"0001812659","reported_name":"Silberstein David S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T16:05:08.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":17307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 12-month period commencing February 9, 2026."}],"balance_after":17307,"derivative":{"exercise_price":3.49,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":17307},"source":{"system":"sec-edgar","filing":"0001493152-26-002027","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1812659/000149315226002027/ownership.xml","form_type":"4"}},{"id":940108,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":69442,"kind":"person","name":"Silberstein David S.","position":1,"cik":"0001812659","reported_name":"Silberstein David S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T16:05:08.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing February 9, 2026."}],"balance_after":25000,"derivative":{"exercise_price":3.49,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001493152-26-002027","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812659/000149315226002027/ownership.xml","form_type":"4"}},{"id":961078,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":70979,"kind":"person","name":"Margrave David R.","position":1,"cik":"0001813162","reported_name":"Margrave David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-22T16:05:25.000Z","date":"2025-12-18","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing January 18, 2026."}],"balance_after":20000,"derivative":{"exercise_price":3.24,"expiration_date":"2035-12-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001493152-25-028759","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813162/000149315225028759/ownership.xml","form_type":"4"}},{"id":961077,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":70978,"kind":"person","name":"Bhatia Kishor G.","position":1,"cik":"0001812638","reported_name":"Bhatia Kishor G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-22T16:05:24.000Z","date":"2025-12-18","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing January 18, 2026."}],"balance_after":10000,"derivative":{"exercise_price":3.24,"expiration_date":"2035-12-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001493152-25-028758","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812638/000149315225028758/ownership.xml","form_type":"4"}},{"id":1033790,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T20:05:13.000Z","date":"2021-11-04","kind":"grant","planned":false,"acquired":true,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on November 4, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing December 4, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on November 4, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing December 4, 2021."}],"balance_after":3200,"derivative":{"exercise_price":5.04,"expiration_date":"2031-11-03","underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0001493152-25-014614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315225014614/ownership.xml","form_type":"4"}},{"id":1033789,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T20:05:13.000Z","date":"2021-11-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on November 4, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing December 4, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on November 4, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing December 4, 2021."}],"balance_after":0,"derivative":{"exercise_price":10.32,"expiration_date":"2031-11-03","underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0001493152-25-014614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315225014614/ownership.xml","form_type":"4"}},{"id":1033788,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T20:05:13.000Z","date":"2020-06-15","kind":"grant","planned":false,"acquired":true,"shares":9135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and provides for vesting in equal monthly increments over a 36-month period commencing July 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and provides for vesting in equal monthly increments over a 36-month period commencing July 15, 2020."}],"balance_after":9135,"derivative":{"exercise_price":5.04,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":9135},"source":{"system":"sec-edgar","filing":"0001493152-25-014614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315225014614/ownership.xml","form_type":"4"}},{"id":1033787,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T20:05:13.000Z","date":"2020-06-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and provides for vesting in equal monthly increments over a 36-month period commencing July 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and provides for vesting in equal monthly increments over a 36-month period commencing July 15, 2020."}],"balance_after":0,"derivative":{"exercise_price":15,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":9135},"source":{"system":"sec-edgar","filing":"0001493152-25-014614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315225014614/ownership.xml","form_type":"4"}},{"id":1033821,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":69443,"kind":"person","name":"Chandru Vijay","position":1,"cik":"0001813367","reported_name":"Chandru Vijay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:18.000Z","date":"2021-11-04","kind":"grant","planned":false,"acquired":true,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on November 4, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing December 4, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on November 4, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing December 4, 2021."}],"balance_after":3200,"derivative":{"exercise_price":5.04,"expiration_date":"2031-11-03","underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0001493152-25-014617","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813367/000149315225014617/ownership.xml","form_type":"4"}},{"id":1033820,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":69443,"kind":"person","name":"Chandru Vijay","position":1,"cik":"0001813367","reported_name":"Chandru Vijay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:18.000Z","date":"2021-11-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on November 4, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing December 4, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on November 4, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing December 4, 2021."}],"balance_after":0,"derivative":{"exercise_price":10.32,"expiration_date":"2031-11-03","underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0001493152-25-014617","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813367/000149315225014617/ownership.xml","form_type":"4"}},{"id":1033819,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":69443,"kind":"person","name":"Chandru Vijay","position":1,"cik":"0001813367","reported_name":"Chandru Vijay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:18.000Z","date":"2020-06-15","kind":"grant","planned":false,"acquired":true,"shares":9135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and provides for vesting in equal monthly increments over a 36-month period commencing July 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and provides for vesting in equal monthly increments over a 36-month period commencing July 15, 2020."}],"balance_after":9135,"derivative":{"exercise_price":5.04,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":9135},"source":{"system":"sec-edgar","filing":"0001493152-25-014617","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813367/000149315225014617/ownership.xml","form_type":"4"}},{"id":1033818,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":69443,"kind":"person","name":"Chandru Vijay","position":1,"cik":"0001813367","reported_name":"Chandru Vijay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:18.000Z","date":"2020-06-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and provides for vesting in equal monthly increments over a 36-month period commencing July 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and provides for vesting in equal monthly increments over a 36-month period commencing July 15, 2020."}],"balance_after":0,"derivative":{"exercise_price":15,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":9135},"source":{"system":"sec-edgar","filing":"0001493152-25-014617","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813367/000149315225014617/ownership.xml","form_type":"4"}},{"id":1033907,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":75041,"kind":"person","name":"SHARMA PANNA","position":1,"cik":"0001157989","reported_name":"SHARMA PANNA","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:16.000Z","date":"2020-06-15","kind":"grant","planned":false,"acquired":true,"shares":76628,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date)."}],"balance_after":76628,"derivative":{"exercise_price":5.04,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":76628},"source":{"system":"sec-edgar","filing":"0001493152-25-014616","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157989/000149315225014616/ownership.xml","form_type":"4"}},{"id":1033906,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":75041,"kind":"person","name":"SHARMA PANNA","position":1,"cik":"0001157989","reported_name":"SHARMA PANNA","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:16.000Z","date":"2020-06-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":76628,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date)."}],"balance_after":0,"derivative":{"exercise_price":15,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":76628},"source":{"system":"sec-edgar","filing":"0001493152-25-014616","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157989/000149315225014616/ownership.xml","form_type":"4"}},{"id":1033809,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":70978,"kind":"person","name":"Bhatia Kishor G.","position":1,"cik":"0001812638","reported_name":"Bhatia Kishor G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:14.000Z","date":"2021-10-29","kind":"grant","planned":false,"acquired":true,"shares":17400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021."}],"balance_after":17400,"derivative":{"exercise_price":5.04,"expiration_date":"2031-10-28","underlying":"Common Stock","underlying_shares":17400},"source":{"system":"sec-edgar","filing":"0001493152-25-014615","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1812638/000149315225014615/ownership.xml","form_type":"4"}},{"id":1033808,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":70978,"kind":"person","name":"Bhatia Kishor G.","position":1,"cik":"0001812638","reported_name":"Bhatia Kishor G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:14.000Z","date":"2021-10-29","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021."}],"balance_after":0,"derivative":{"exercise_price":10.21,"expiration_date":"2031-10-28","underlying":"Common Stock","underlying_shares":17400},"source":{"system":"sec-edgar","filing":"0001493152-25-014615","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1812638/000149315225014615/ownership.xml","form_type":"4"}},{"id":1033807,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":70978,"kind":"person","name":"Bhatia Kishor G.","position":1,"cik":"0001812638","reported_name":"Bhatia Kishor G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:14.000Z","date":"2020-06-15","kind":"grant","planned":false,"acquired":true,"shares":52200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date)."}],"balance_after":52200,"derivative":{"exercise_price":5.04,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":52200},"source":{"system":"sec-edgar","filing":"0001493152-25-014615","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1812638/000149315225014615/ownership.xml","form_type":"4"}},{"id":1033806,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":70978,"kind":"person","name":"Bhatia Kishor G.","position":1,"cik":"0001812638","reported_name":"Bhatia Kishor G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:14.000Z","date":"2020-06-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":52200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date)."}],"balance_after":0,"derivative":{"exercise_price":15,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":52200},"source":{"system":"sec-edgar","filing":"0001493152-25-014615","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812638/000149315225014615/ownership.xml","form_type":"4"}},{"id":1033817,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":70979,"kind":"person","name":"Margrave David R.","position":1,"cik":"0001813162","reported_name":"Margrave David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:11.000Z","date":"2021-10-29","kind":"grant","planned":false,"acquired":true,"shares":26100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021."}],"balance_after":26100,"derivative":{"exercise_price":5.04,"expiration_date":"2031-10-28","underlying":"Common Stock","underlying_shares":26100},"source":{"system":"sec-edgar","filing":"0001493152-25-014612","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813162/000149315225014612/ownership.xml","form_type":"4"}},{"id":1033816,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":70979,"kind":"person","name":"Margrave David R.","position":1,"cik":"0001813162","reported_name":"Margrave David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:11.000Z","date":"2021-10-29","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021."}],"balance_after":0,"derivative":{"exercise_price":10.21,"expiration_date":"2031-10-28","underlying":"Common Stock","underlying_shares":26100},"source":{"system":"sec-edgar","filing":"0001493152-25-014612","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813162/000149315225014612/ownership.xml","form_type":"4"}},{"id":1033815,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":70979,"kind":"person","name":"Margrave David R.","position":1,"cik":"0001813162","reported_name":"Margrave David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:11.000Z","date":"2020-06-15","kind":"grant","planned":false,"acquired":true,"shares":78300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date)."}],"balance_after":78300,"derivative":{"exercise_price":5.04,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":78300},"source":{"system":"sec-edgar","filing":"0001493152-25-014612","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813162/000149315225014612/ownership.xml","form_type":"4"}},{"id":1033814,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":70979,"kind":"person","name":"Margrave David R.","position":1,"cik":"0001813162","reported_name":"Margrave David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:11.000Z","date":"2020-06-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":78300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date)."}],"balance_after":0,"derivative":{"exercise_price":15,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":78300},"source":{"system":"sec-edgar","filing":"0001493152-25-014612","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813162/000149315225014612/ownership.xml","form_type":"4"}},{"id":1033813,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":69442,"kind":"person","name":"Silberstein David S.","position":1,"cik":"0001812659","reported_name":"Silberstein David S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:09.000Z","date":"2021-11-04","kind":"grant","planned":false,"acquired":true,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on November 4, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing December 4, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on November 4, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing December 4, 2021."}],"balance_after":3200,"derivative":{"exercise_price":5.04,"expiration_date":"2031-11-03","underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0001493152-25-014611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1812659/000149315225014611/ownership.xml","form_type":"4"}},{"id":1033812,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":69442,"kind":"person","name":"Silberstein David S.","position":1,"cik":"0001812659","reported_name":"Silberstein David S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:09.000Z","date":"2021-11-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on November 4, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing December 4, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on November 4, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing December 4, 2021."}],"balance_after":0,"derivative":{"exercise_price":10.32,"expiration_date":"2031-11-03","underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0001493152-25-014611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1812659/000149315225014611/ownership.xml","form_type":"4"}},{"id":1033811,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":69442,"kind":"person","name":"Silberstein David S.","position":1,"cik":"0001812659","reported_name":"Silberstein David S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:09.000Z","date":"2020-06-15","kind":"grant","planned":false,"acquired":true,"shares":9135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and provides for vesting in equal monthly increments over a 36-month period commencing July 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and provides for vesting in equal monthly increments over a 36-month period commencing July 15, 2020."}],"balance_after":9135,"derivative":{"exercise_price":5.04,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":9135},"source":{"system":"sec-edgar","filing":"0001493152-25-014611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1812659/000149315225014611/ownership.xml","form_type":"4"}},{"id":1033810,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":69442,"kind":"person","name":"Silberstein David S.","position":1,"cik":"0001812659","reported_name":"Silberstein David S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T16:05:09.000Z","date":"2020-06-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and provides for vesting in equal monthly increments over a 36-month period commencing July 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and provides for vesting in equal monthly increments over a 36-month period commencing July 15, 2020."}],"balance_after":0,"derivative":{"exercise_price":15,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":9135},"source":{"system":"sec-edgar","filing":"0001493152-25-014611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812659/000149315225014611/ownership.xml","form_type":"4"}},{"id":1060355,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47355,"kind":"person","name":"Schalop Lee Troy","position":1,"cik":"0002072339","reported_name":"Schalop Lee Troy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-20T22:25:16.000Z","date":"2025-08-19","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Equity Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 36-month period commencing September 19, 2025."}],"balance_after":5000,"derivative":{"exercise_price":4.46,"expiration_date":"2035-08-18","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001641172-25-025000","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000164117225025000/ownership.xml","form_type":"4"}},{"id":1111847,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:57:00.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":4354,"price":3.09,"value":13453.86,"ownership":{"direct":false,"nature":"by Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 13, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.05 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":114272,"source":{"system":"sec-edgar","filing":"0001104659-25-059528","document":"tm2518021-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059528/tm2518021-2_4seq1.xml","form_type":"4"}},{"id":1111846,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:57:00.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":14218,"price":3.09,"value":43933.62,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 13, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.05 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":373178,"source":{"system":"sec-edgar","filing":"0001104659-25-059528","document":"tm2518021-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059528/tm2518021-2_4seq1.xml","form_type":"4"}},{"id":1111845,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:57:00.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":1903,"price":3.09,"value":5880.27,"ownership":{"direct":false,"nature":"By Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 13, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.05 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":49957,"source":{"system":"sec-edgar","filing":"0001104659-25-059528","document":"tm2518021-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059528/tm2518021-2_4seq1.xml","form_type":"4"}},{"id":1111844,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:57:00.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":12319,"price":3.09,"value":38065.71,"ownership":{"direct":false,"nature":"By Bios Fund I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 13, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.05 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":323335,"source":{"system":"sec-edgar","filing":"0001104659-25-059528","document":"tm2518021-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059528/tm2518021-2_4seq1.xml","form_type":"4"}},{"id":1111843,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:57:00.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":7206,"price":3.09,"value":22266.54,"ownership":{"direct":false,"nature":"By Bios Fund I QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 13, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.05 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":189117,"source":{"system":"sec-edgar","filing":"0001104659-25-059528","document":"tm2518021-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059528/tm2518021-2_4seq1.xml","form_type":"4"}},{"id":1111826,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T19:50:41.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":4354,"price":3.09,"value":13453.86,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 13, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.05 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":114272,"source":{"system":"sec-edgar","filing":"0001104659-25-059526","document":"tm2518021-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059526/tm2518021-1_4seq1.xml","form_type":"4"}},{"id":1111825,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T19:50:41.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":14218,"price":3.09,"value":43933.62,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 13, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.05 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":373178,"source":{"system":"sec-edgar","filing":"0001104659-25-059526","document":"tm2518021-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059526/tm2518021-1_4seq1.xml","form_type":"4"}},{"id":1111824,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T19:50:41.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":1903,"price":3.09,"value":5880.27,"ownership":{"direct":false,"nature":"By Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 13, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.05 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":49957,"source":{"system":"sec-edgar","filing":"0001104659-25-059526","document":"tm2518021-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059526/tm2518021-1_4seq1.xml","form_type":"4"}},{"id":1111823,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T19:50:41.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":12319,"price":3.09,"value":38065.71,"ownership":{"direct":false,"nature":"By Bios Fund I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 13, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.05 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":323335,"source":{"system":"sec-edgar","filing":"0001104659-25-059526","document":"tm2518021-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059526/tm2518021-1_4seq1.xml","form_type":"4"}},{"id":1111822,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T19:50:41.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":7206,"price":3.09,"value":22266.54,"ownership":{"direct":false,"nature":"By Bios Fund I QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 13, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.05 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":189117,"source":{"system":"sec-edgar","filing":"0001104659-25-059526","document":"tm2518021-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059526/tm2518021-1_4seq1.xml","form_type":"4"}},{"id":1111841,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":6601,"price":3.38,"value":22311.38,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 12, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.57 to $3.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":118626,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111840,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-11","kind":"sale","planned":false,"acquired":false,"shares":103,"price":3.4,"value":350.2,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":125227,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111839,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-10","kind":"sale","planned":false,"acquired":false,"shares":2,"price":3.4,"value":6.8,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":125330,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111838,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":21557,"price":3.38,"value":72862.66,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 12, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.57 to $3.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":387396,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111837,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-11","kind":"sale","planned":false,"acquired":false,"shares":338,"price":3.4,"value":1149.2,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":408953,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111836,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-10","kind":"sale","planned":false,"acquired":false,"shares":5,"price":3.4,"value":17.0,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":409291,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111835,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":2886,"price":3.38,"value":9754.68,"ownership":{"direct":false,"nature":"By Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 12, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.57 to $3.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":51860,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111834,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-11","kind":"sale","planned":false,"acquired":false,"shares":45,"price":3.4,"value":153.0,"ownership":{"direct":false,"nature":"By Bios Fund II NT, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":54746,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111833,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-10","kind":"sale","planned":false,"acquired":false,"shares":1,"price":3.4,"value":3.4,"ownership":{"direct":false,"nature":"By Bios Fund II NT, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":54791,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111832,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":18678,"price":3.38,"value":63131.64,"ownership":{"direct":false,"nature":"By Bios Fund I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 12, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.57 to $3.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":335654,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111831,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-11","kind":"sale","planned":false,"acquired":false,"shares":293,"price":3.4,"value":996.2,"ownership":{"direct":false,"nature":"By Bios Fund I, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":354332,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111830,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-10","kind":"sale","planned":false,"acquired":false,"shares":5,"price":3.4,"value":17.0,"ownership":{"direct":false,"nature":"By Bios Fund I, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":354625,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111829,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":10925,"price":3.38,"value":36926.5,"ownership":{"direct":false,"nature":"By Bios Fund I QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 12, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.57 to $3.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":196323,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111828,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-11","kind":"sale","planned":false,"acquired":false,"shares":171,"price":3.4,"value":581.4,"ownership":{"direct":false,"nature":"By Bios Fund I QP, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":207248,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111827,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T10:06:49.000Z","date":"2025-06-10","kind":"sale","planned":false,"acquired":false,"shares":3,"price":3.4,"value":10.2,"ownership":{"direct":false,"nature":"By Bios Fund I QP, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":207419,"source":{"system":"sec-edgar","filing":"0001104659-25-059106","document":"tm2517905-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925059106/tm2517905-2_4seq1.xml","form_type":"4"}},{"id":1111821,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T06:01:21.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":6601,"price":3.38,"value":22311.38,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 12, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.57 to $3.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":118626,"source":{"system":"sec-edgar","filing":"0001104659-25-059091","document":"tm2517905-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059091/tm2517905-1_4seq1.xml","form_type":"4"}},{"id":1111820,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T06:01:21.000Z","date":"2025-06-11","kind":"sale","planned":false,"acquired":false,"shares":103,"price":3.4,"value":350.2,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":125227,"source":{"system":"sec-edgar","filing":"0001104659-25-059091","document":"tm2517905-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059091/tm2517905-1_4seq1.xml","form_type":"4"}},{"id":1111819,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T06:01:21.000Z","date":"2025-06-10","kind":"sale","planned":false,"acquired":false,"shares":2,"price":3.4,"value":6.8,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":125330,"source":{"system":"sec-edgar","filing":"0001104659-25-059091","document":"tm2517905-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059091/tm2517905-1_4seq1.xml","form_type":"4"}},{"id":1111818,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T06:01:21.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":21557,"price":3.38,"value":72862.66,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 12, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.57 to $3.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":387396,"source":{"system":"sec-edgar","filing":"0001104659-25-059091","document":"tm2517905-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059091/tm2517905-1_4seq1.xml","form_type":"4"}},{"id":1111817,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T06:01:21.000Z","date":"2025-06-11","kind":"sale","planned":false,"acquired":false,"shares":338,"price":3.4,"value":1149.2,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":408953,"source":{"system":"sec-edgar","filing":"0001104659-25-059091","document":"tm2517905-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059091/tm2517905-1_4seq1.xml","form_type":"4"}},{"id":1111816,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T06:01:21.000Z","date":"2025-06-10","kind":"sale","planned":false,"acquired":false,"shares":5,"price":3.4,"value":17.0,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":409291,"source":{"system":"sec-edgar","filing":"0001104659-25-059091","document":"tm2517905-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059091/tm2517905-1_4seq1.xml","form_type":"4"}},{"id":1111815,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T06:01:21.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":2886,"price":3.38,"value":9754.68,"ownership":{"direct":false,"nature":"By Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 12, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.57 to $3.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":51860,"source":{"system":"sec-edgar","filing":"0001104659-25-059091","document":"tm2517905-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059091/tm2517905-1_4seq1.xml","form_type":"4"}},{"id":1111814,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T06:01:21.000Z","date":"2025-06-11","kind":"sale","planned":false,"acquired":false,"shares":45,"price":3.4,"value":153.0,"ownership":{"direct":false,"nature":"By Bios Fund II NT, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":54746,"source":{"system":"sec-edgar","filing":"0001104659-25-059091","document":"tm2517905-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059091/tm2517905-1_4seq1.xml","form_type":"4"}},{"id":1111813,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T06:01:21.000Z","date":"2025-06-10","kind":"sale","planned":false,"acquired":false,"shares":1,"price":3.4,"value":3.4,"ownership":{"direct":false,"nature":"By Bios Fund II NT, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":54791,"source":{"system":"sec-edgar","filing":"0001104659-25-059091","document":"tm2517905-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059091/tm2517905-1_4seq1.xml","form_type":"4"}},{"id":1111812,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T06:01:21.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":18678,"price":3.38,"value":63131.64,"ownership":{"direct":false,"nature":"By Bios Fund I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 12, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.57 to $3.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":335654,"source":{"system":"sec-edgar","filing":"0001104659-25-059091","document":"tm2517905-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059091/tm2517905-1_4seq1.xml","form_type":"4"}},{"id":1111811,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T06:01:21.000Z","date":"2025-06-11","kind":"sale","planned":false,"acquired":false,"shares":293,"price":3.4,"value":996.2,"ownership":{"direct":false,"nature":"By Bios Fund I, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":354332,"source":{"system":"sec-edgar","filing":"0001104659-25-059091","document":"tm2517905-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059091/tm2517905-1_4seq1.xml","form_type":"4"}},{"id":1111810,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T06:01:21.000Z","date":"2025-06-10","kind":"sale","planned":false,"acquired":false,"shares":5,"price":3.4,"value":17.0,"ownership":{"direct":false,"nature":"By Bios Fund I, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":354625,"source":{"system":"sec-edgar","filing":"0001104659-25-059091","document":"tm2517905-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059091/tm2517905-1_4seq1.xml","form_type":"4"}},{"id":1111809,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T06:01:21.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":10925,"price":3.38,"value":36926.5,"ownership":{"direct":false,"nature":"By Bios Fund I QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On June 12, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $3.57 to $3.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":196323,"source":{"system":"sec-edgar","filing":"0001104659-25-059091","document":"tm2517905-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059091/tm2517905-1_4seq1.xml","form_type":"4"}},{"id":1111808,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T06:01:21.000Z","date":"2025-06-11","kind":"sale","planned":false,"acquired":false,"shares":171,"price":3.4,"value":581.4,"ownership":{"direct":false,"nature":"By Bios Fund I QP, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":207248,"source":{"system":"sec-edgar","filing":"0001104659-25-059091","document":"tm2517905-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059091/tm2517905-1_4seq1.xml","form_type":"4"}},{"id":1111807,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T06:01:21.000Z","date":"2025-06-10","kind":"sale","planned":false,"acquired":false,"shares":3,"price":3.4,"value":10.2,"ownership":{"direct":false,"nature":"By Bios Fund I QP, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":207419,"source":{"system":"sec-edgar","filing":"0001104659-25-059091","document":"tm2517905-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925059091/tm2517905-1_4seq1.xml","form_type":"4"}},{"id":1130645,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-29","kind":"sale","planned":false,"acquired":false,"shares":2199,"price":3.03,"value":6662.97,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":125332,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130644,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-28","kind":"sale","planned":false,"acquired":false,"shares":1632,"price":2.87,"value":4683.84,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":127531,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130643,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-27","kind":"sale","planned":false,"acquired":false,"shares":2290,"price":3.05,"value":6984.5,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":129163,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130642,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-29","kind":"sale","planned":false,"acquired":false,"shares":7180,"price":3.03,"value":21755.4,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":409296,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130641,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-28","kind":"sale","planned":false,"acquired":false,"shares":5332,"price":2.87,"value":15302.84,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":416476,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130640,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-27","kind":"sale","planned":false,"acquired":false,"shares":7478,"price":3.05,"value":22807.9,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":421808,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130639,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-29","kind":"sale","planned":false,"acquired":false,"shares":961,"price":3.03,"value":2911.83,"ownership":{"direct":false,"nature":"By Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":54792,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130638,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-28","kind":"sale","planned":false,"acquired":false,"shares":714,"price":2.87,"value":2049.18,"ownership":{"direct":false,"nature":"By Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":55753,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130637,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-27","kind":"sale","planned":false,"acquired":false,"shares":1000,"price":3.05,"value":3050.0,"ownership":{"direct":false,"nature":"By Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":56467,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130636,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-29","kind":"sale","planned":false,"acquired":false,"shares":6221,"price":3.03,"value":18849.63,"ownership":{"direct":false,"nature":"By Bios Fund I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":354630,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130635,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-28","kind":"sale","planned":false,"acquired":false,"shares":4620,"price":2.87,"value":13259.4,"ownership":{"direct":false,"nature":"By Bios Fund I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":360851,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130634,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-27","kind":"sale","planned":false,"acquired":false,"shares":6479,"price":3.05,"value":19760.95,"ownership":{"direct":false,"nature":"By Bios Fund I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":365471,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130633,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-29","kind":"sale","planned":false,"acquired":false,"shares":3639,"price":3.03,"value":11026.17,"ownership":{"direct":false,"nature":"By Bios Fund I QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":207422,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130632,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-28","kind":"sale","planned":false,"acquired":false,"shares":2702,"price":2.87,"value":7754.74,"ownership":{"direct":false,"nature":"By Bios Fund I QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":211061,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130631,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36362,"kind":"person","name":"BIOS Fund I, LP","position":2,"cik":"0001697316","reported_name":"BIOS Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36367,"kind":"person","name":"BIOS Fund I QP, LP","position":3,"cik":"0001700297","reported_name":"BIOS Fund I QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36366,"kind":"person","name":"BIOS Fund II, LP","position":4,"cik":"0001714576","reported_name":"BIOS Fund II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36363,"kind":"person","name":"BIOS Fund II QP, LP","position":5,"cik":"0001716869","reported_name":"BIOS Fund II QP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77973,"kind":"person","name":"BIOS Fund II NT, LP","position":6,"cik":"0001728851","reported_name":"BIOS Fund II NT, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36361,"kind":"person","name":"Bios Equity Partners, LP","position":7,"cik":"0001813314","reported_name":"Bios Equity Partners, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36365,"kind":"person","name":"Bios Equity Partners II, LP","position":8,"cik":"0001813313","reported_name":"Bios Equity Partners II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":9,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":10,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-30T01:55:55.000Z","date":"2025-05-27","kind":"sale","planned":false,"acquired":false,"shares":3790,"price":3.05,"value":11559.5,"ownership":{"direct":false,"nature":"By Bios Fund I QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":213763,"source":{"system":"sec-edgar","filing":"0001104659-25-054422","document":"tm2516511-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813845/000110465925054422/tm2516511-2_4seq1.xml","form_type":"4"}},{"id":1130629,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-29T21:53:24.000Z","date":"2025-05-29","kind":"sale","planned":false,"acquired":false,"shares":2199,"price":3.03,"value":6662.97,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":125332,"source":{"system":"sec-edgar","filing":"0001104659-25-054421","document":"tm2516511-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925054421/tm2516511-1_4seq1.xml","form_type":"4"}},{"id":1130628,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-29T21:53:24.000Z","date":"2025-05-28","kind":"sale","planned":false,"acquired":false,"shares":1632,"price":2.87,"value":4683.84,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":127531,"source":{"system":"sec-edgar","filing":"0001104659-25-054421","document":"tm2516511-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925054421/tm2516511-1_4seq1.xml","form_type":"4"}},{"id":1130627,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-29T21:53:24.000Z","date":"2025-05-27","kind":"sale","planned":false,"acquired":false,"shares":2290,"price":3.05,"value":6984.5,"ownership":{"direct":false,"nature":"By Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":129163,"source":{"system":"sec-edgar","filing":"0001104659-25-054421","document":"tm2516511-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925054421/tm2516511-1_4seq1.xml","form_type":"4"}},{"id":1130626,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-29T21:53:24.000Z","date":"2025-05-29","kind":"sale","planned":false,"acquired":false,"shares":7180,"price":3.03,"value":21755.4,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":409296,"source":{"system":"sec-edgar","filing":"0001104659-25-054421","document":"tm2516511-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925054421/tm2516511-1_4seq1.xml","form_type":"4"}},{"id":1130625,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-29T21:53:24.000Z","date":"2025-05-28","kind":"sale","planned":false,"acquired":false,"shares":5332,"price":2.87,"value":15302.84,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":416476,"source":{"system":"sec-edgar","filing":"0001104659-25-054421","document":"tm2516511-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925054421/tm2516511-1_4seq1.xml","form_type":"4"}},{"id":1130624,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":77970,"kind":"person","name":"Kreis Leslie W.","position":1,"cik":"0001813316","reported_name":"Kreis Leslie W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77972,"kind":"person","name":"Cavu Management, LP","position":2,"cik":"0001813270","reported_name":"Cavu Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77971,"kind":"person","name":"Cavu Advisors, LLC","position":3,"cik":"0001813310","reported_name":"Cavu Advisors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":77990,"kind":"person","name":"BP Directors, LP","position":4,"cik":"0001813311","reported_name":"BP Directors, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-29T21:53:24.000Z","date":"2025-05-27","kind":"sale","planned":false,"acquired":false,"shares":7478,"price":3.05,"value":22807.9,"ownership":{"direct":false,"nature":"By Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP (\"Bios Fund I QP\"), Bios Fund I, LP (\"Bios Fund I\"), Bios Fund II NT, LP (\"Bios Fund II NT\"), Bios Fund II QP, LP (\"Bios Fund II QP\") and Bios Fund II, LP (\"Bios Fund II\") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP (\"Bios Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (\"Cavu Management\"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP (\"Bios Management\"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC (\"Cavu Advisors\"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC (\"Bios Advisors\"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the \"Bios Equity Entities\"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":421808,"source":{"system":"sec-edgar","filing":"0001104659-25-054421","document":"tm2516511-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1813270/000110465925054421/tm2516511-1_4seq1.xml","form_type":"4"}}],"next_cursor":"2025-05-29T21:53:24.000000Z,1130624"}